ArticleJournal of neuro-oncology2026
Cesium-131 brachytherapy for central nervous system salvage therapy.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSalvage therapy for metastatic central nervous system (CNS) lesions remains challenging. Repeat stereotactic radiosurgery (SRS) is sometimes feasible, but subject to high radionecrosis rates. Cesium-131 (Cs-131) brachytherapy seeds packaged inside “tiles” of collagen spacer material may offer an alternative approach. We report a single institution’s experience with this modality.
methodsPatients with metastatic lesions salvaged with Cs-131 brachytherapy were reviewed. Analyses included treatment characteristics and Kaplan–Meier estimates of overall survival (OS) and local control, while primary tumor outcomes were summarized descriptively.
resultsSixteen patients with metastatic lesions (19 post-operative resection cavities, 17 cases) were reviewed. The most common primary histologies were non-small cell lung cancer (8 cavities, 42.1%) and invasive ductal carcinoma of the breast (3 cavities, 15.8%). One year OS was 70.8%. During follow-up, local failure occurred in 2 of 19 cavities (10.5%). Gross-total resection (GTR) was achieved in 15 cavities (78.9%). All demonstrated local control at a median follow-up of 12 months (full range, 2–39 months). Subtotal or near-total resection (STR/NTR) was achieved in 4 cavities (21.1%). Follow-up data were available for 2 of these cavities (both NTR), and both experienced local failure at 5.3 months. Postoperative cerebrospinal fluid (CSF) leak occurred in 2 patients (12.5%). Radionecrosis within the resection cavity was observed in 3 patients (18.8%) with symptomatic grade ≥ 2 radionecrosis occurring in 1 patient (6.3%).
conclusionsSalvage therapy with Cs-131 brachytherapy offers effective local control and an acceptable safety profile. Its utility may be greatest following GTR.
Indexed as
Identifiers
41910853What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.